Products of AbbVie (China)

Abway has rich experience in drug research and development, and has been committed to drug research and development for more than 125 years. In China, AbbVie focuses on immunology, virology, nephrology and anesthesiology, and its patented products and mature products are growing rapidly, including Humira, Kaletra/Aluvia, Calcijex and sevoflurane. Zemplar is the world's first vitamin D receptor agonist, which is used to prevent and treat "secondary hyperparathyroidism in patients with chronic renal failure undergoing hemodialysis" related to chronic renal diseases. It has been listed in more than 60 countries around the world, and was approved to be listed in China in 20 13.

Calcijex is the first calcitriol injection in China, which is suitable for the treatment of hypocalcemia in chronic renal dialysis patients. It can obviously reduce the elevated PTH level of many patients, reduce the absorption of calcium and phosphorus in gastrointestinal tract, improve the compliance of patients, reduce food leakage, and be more conducive to disease management.

In addition to the product portfolio that has been launched in China, more than 20 products of AbbVie are in the middle and late stages of clinical trials. At the same time, we have developed new medical products and methods for hepatitis C, rheumatoid arthritis, plaque psoriasis, renal failure, multiple sclerosis, Alzheimer's disease, Parkinson's disease, spinal arthritis, multiple myeloma and endometriosis.

Abway is committed to promoting innovative ways of flexible cooperation in R&D centers and production bases around the world. AbbVie (China) R&D Center was completed as early as 2009, and it is one of the seven R&D centers in AbbVie. The R&D center in China supports the global drug R&D department (GPRD), which focuses on the fields of immunity, pain, nervous system and kidney diseases.